Northwest Agriculture & Forestry University has described thiazolecarboxamidine compounds acting as NADH-ubiquinone oxidoreductase (complex I) inhibitors reported to be useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified macrocyclic compounds acting as GTPase KRAS (G12C) mutant inhibitors reported to be useful for the treatment of cancer.
Institute of Rheological Function of Food Co. Ltd. and Kyushu University have synthesized plasmalogen derivatives reported to be useful for the treatment of dementia, Rett syndrome, Parkinson’s disease, depression and schizophrenia.
Facioscapulohumeral muscular dystrophy (FSHD) is a skeletal muscular dystrophy characterized by DNA hypomethylation of D4Z4 repeat units of a macrosatellite array found at the distal end of chromosome region 4q35, which causes a myotoxic expression of DUX4. Researchers from Epic-Bio presented the discovery of EPI-321, a novel gene therapy candidate for the treatment of FSHD.
When tissue injury occurs, stressed cells release a bunch of intracellular molecules called damage-associated molecular pattern (DAMP) proteins. S100 calcium binding protein A9 (S100A9) is a DAMP usually found in macrophages and is involved in multiple inflammatory responses, such as activation of Toll-like receptor 4 (TLR4).
Evaxion Biotech A/S has developed a new proprietary artificial intelligence (AI) platform technology, Observ, to identify a new source of targets for personalized cancer therapy, potentially enabling treatment for patients with cold tumors, normally unresponsive to immunotherapy.
RSS
